Evidence map›Paper›PMID 26573178›Full record

ReviewFuture microbiology2015

Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Zarmina Ehsan, John P Clancy

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Role of inhaled antibiotics in the era of highly effective CFTR modulators.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  6. Review
  7. Clinical Advances in Cystic Fibrosis.Journal of clinical medicine · 2022
    Article
  8. Vaccines · 2022
    Review
  9. Aminoglycoside-Modifying Enzymes Are Sufficient to MakeAntibiotics (Basel, Switzerland) · 2022
    Article
  10. Impact of Patient-Specific Aminoglycoside Monitoring for Treatment of Pediatric Cystic Fibrosis Pulmonary Exacerbations.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Positive Effect of Liposomal Amikacin for Inhalation onOpen forum infectious diseases · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zarmina EhsanDivision of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center & the University of Cincinnati, MLC 2021 3333 Burnet Avenue, Cincinnati, OH 45220, USA.
John P ClancyDivision of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center & the University of Cincinnati, MLC 2021 3333 Burnet Avenue, Cincinnati, OH 45220, USA.
University of Cincinnati · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
MR predictors of infection, inflammation, and structural lung damage in CFR01HL116226 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI CLANCY, JOHN PAUL · 2012 to 2015
$2.1M
NCATS NIH HHS UL1 TR001425NHLBI NIH HHS 5R01HL116226-02NHLBI NIH HHS R01 HL116226
6 · The paper itself

Abstract

Pseudomonas aeruginosa (PsA) is a highly prevalent bacterial organism recovered from the lungs of cystic fibrosis (CF) patients and chronic PsA infection is linked to progressive pulmonary function decline. The eradication and treatment of this organism from CF airways is particularly challenging to CF care providers. Aerosolized antibiotics that target PsA help to slow down growth, maintain lung function and reduce the frequency of pulmonary exacerbations. In this review, we discuss the currently available inhaled antibiotics for management of PsA lung infections in CF patients, with a focus on liposomal amikacin for inhalation (LAI). LAI is a unique formulation of amikacin under development that enhances drug delivery and retention in CF airways via drug incorporation into neutral liposomes. Factors such as once-daily dosing, mucus and biofilm penetration and potentially prolonged off-drug periods make LAI a potentially attractive option to manage chronic PsA lung infections in CF patients.

Indexed as

Administration, InhalationAerosolsAmikacinAnti-Bacterial AgentsCystic FibrosisDrug CarriersHumansLiposomesPneumonia, BacterialPseudomonas aeruginosaPseudomonas InfectionsAerosolsAmikacinAnti-Bacterial AgentsDrug CarriersLiposomesamikacinarikacearikaycecystic fibrosisLAIPseudomonas aeruginosa

Identifiers

PMID26573178
PMCPMC4944396
OpenAlexW2179062574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.